63
Participants
Start Date
October 15, 2018
Primary Completion Date
January 3, 2020
Study Completion Date
October 21, 2020
UGN-102
"UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL)."
Manhattan Medical Research, New York
Weill Cornell Medical College, New York
Montefiore Medical Center (Albert Einstein), New York
Western New York Urology Associates, New York
Penn State Hershey State College, Hershey
John Hopkins University, Baltimore
The University of North Carolina, Chapel Hill
Carolina Urologic Research Center, Myrtle Beach
Clinical Research Center of Florida, Pompano Beach
Urology Associates, PC, Nashville
Rabin Medical Center, Petah Tikva
Adult & Pediatric Urology, PC, Omaha
Arkansas Urology, Little Rock
Urology San Antonio, Fredericksburg
Mayo Clinic Cancer Center, Phoenix
Urology Las Vegas, Las Vegas
Providence Medical Institute, Santa Monica
Loma Linda University, Loma Linda
Carmel Medical Center, Haifa
UroGen Pharma Ltd.
INDUSTRY